Proteome SciencesPMSNF ROC (Joel Greenblatt) % is -90.94% as of Dec. 2025. The stock has 6 warning signs investors should review. Among 211 Medical Diagnostics & Research companies, Proteome Sciences ranks worse than 73.93% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Proteome Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -90.94%.
The historical rank and industry rank for Proteome Sciences's ROC (Joel Greenblatt) % or its related term are showing as below:
PMSNF'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -152.61 Med: -58.91 Max: 71.43
Current: -111.72
During the past 13 years, Proteome Sciences's highest ROC (Joel Greenblatt) % was 71.43%. The lowest was -152.61%. And the median was -58.91%.
PMSNF's ROC (Joel Greenblatt) % is ranked worse than 73.93% of 211
companies
in the Medical Diagnostics & Research industry
Industry Median: -3.02
vs PMSNF: -111.72
Proteome Sciences's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Proteome Sciences ROC (Joel Greenblatt) % Related Terms
Proteome Sciences ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Proteome Sciences's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PMSNF vs TMO, DHR, IDXX: ROC (Joel Greenblatt) % Comparison
For the Diagnostics & Research subindustry, Proteome Sciences's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Proteome Sciences ROC (Joel Greenblatt) % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Proteome Sciences's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Proteome Sciences's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of -90.94% mean?
Proteome Sciences (PMSNF) has a ROC (Joel Greenblatt) % of -90.94% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Proteome Sciences and its competitors. According to the industry distribution chart, Proteome Sciences ranks #156 out of 211 companies in the Medical Diagnostics & Research industry, placing it in the top 73.9%.
Is Proteome Sciences' ROC (Joel Greenblatt) % too high?
Proteome Sciences' current ROC (Joel Greenblatt) % is -90.94%. Based on the distribution chart, Proteome Sciences ranks #156 out of 211 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint.
How does Proteome Sciences' ROC (Joel Greenblatt) % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Proteome Sciences ranks #156 out of 211 companies for ROC (Joel Greenblatt) %. This places Proteome Sciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Diagnostics & Research company?
A good ROC (Joel Greenblatt) % depends on the Medical Diagnostics & Research industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Proteome Sciences and its competitors. Proteome Sciences's current ROC (Joel Greenblatt) % is -90.94%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Proteome Sciences stock overvalued right now?
Proteome Sciences (PMSNF) has a current ROC (Joel Greenblatt) % of -90.94%. The stock's GF Value™ is $0.03, compared to a current price of $0.02 — trading 17.5% below its estimated fair value. The current ROC (Joel Greenblatt) % is -90.94%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Proteome Sciences (PMSNF), the current ROC (Joel Greenblatt) % is -90.94% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Proteome Sciences PLC is engaged in protein biomarker research and development. The company is a provider of contract research services for the identification, validation and application of protein biomarkers. The company's only reportable segment is the sale of goods and biomarker services. The company generates maximum revenue from the TMT product and end customer sales-based royalties. Geographically, it has a presence in the United States, the United Kingdom, the European Union, and Others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PMSNF has been successfully added to your 